Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - Moderna reported a quarterly loss of $0.51 per share, significantly better than the Zacks Consensus Estimate of a loss of $2.15, representing an earnings surprise of +76.28% [1] - The company generated revenues of $1.02 billion for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 18.13%, although this is a decline from $1.86 billion in the same quarter last year [2] - Moderna has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] Financial Performance - The earnings report indicates a loss of $0.51 per share compared to a profit of $0.03 per share a year ago, adjusted for non-recurring items [1] - The company has shown a mixed trend in estimate revisions ahead of the earnings release, currently holding a Zacks Rank 3 (Hold), suggesting expected performance in line with the market [6] - Current consensus EPS estimate for the upcoming quarter is -$2.90 on revenues of $805.49 million, and for the current fiscal year, it is -$9.74 on revenues of $1.9 billion [7] Market Context - Moderna shares have declined approximately 43.3% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] - The Medical - Biomedical and Genetics industry, to which Moderna belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - The performance of Moderna's stock may also be influenced by the earnings outlook and trends in earnings estimate revisions, which have shown a strong correlation with near-term stock movements [5]